New treatments for common cardiovascular risk factor Lp(a) near market, billions at stake

Lipoprotein(a), a genetically determined cardiovascular risk factor carried by an estimated one in five people worldwide, has no approved treatment on the market, according to STAT News. Elevated Lp(a) raises the risk of heart attack and stroke independent of cholesterol levels, and unlike LDL cholesterol, it cannot currently be lowered through diet, exercise, or existing medications such as statins.

STAT reports that several drugmakers are now advancing therapies aimed at reducing Lp(a), with clinical programs from Novartis, Amgen, and Eli Lilly among those nearing potential market entry. The report frames the competition as significant both medically and commercially, citing analysts’ expectations that a successful Lp(a)-lowering drug could reach blockbuster sales given the size of the affected population and the current absence of any approved alternative.

The article notes that the unmet need stems partly from the difficulty of the underlying biology, since Lp(a) levels are largely inherited and not significantly modified by lifestyle changes. This has left physicians with tools to measure the risk but few means to address it directly in patients found to carry elevated levels.

STAT’s coverage situates the pending treatments within ongoing efforts to close gaps in cardiovascular prevention, noting that regulatory and clinical milestones for these programs are approaching. Further specifics on trial data, timelines, and company strategies are detailed in the full STAT+ report.